Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 50 of the 54 references it cites were found in a registry or an index.

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

Open access

Abstract

Mantle cell lymphoma (MCL) carries an unfavorable prognosis and requires new treatment strategies. The associated t(11:14) translocation results in enhanced cyclin D1 expression and cyclin D1-dependent kinase activity to promote cell-cycle progression. A pharmacodynamic study of the selective CDK4/6 inhibitor PD0332991 was conducted in 17 patients with relapsed disease, using 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG) and 3-deoxy-3[(18)F]fluorothymidine (FLT) positron emission tomography (PET) to study tumor metabolism and proliferation, respectively, in concert with pre- and on-treatment lymph node biopsies to assess retinoblastoma protein (Rb) phosphorylation and markers of proliferation and apoptosis. Substantial reductions in the summed FLT-PET maximal standard uptake value (SUV(max)), as well as in Rb phosphorylation and Ki-67 expression, occurred after 3 weeks in most patients, with significant correlations among these end points. Five patients achieved progression-free survival time of > 1 year (range, 14.9-30.1+ months), with 1 complete and 2 partial responses (18% objective response rate; 90% confidence interval, 5%-40%). These patients demonstrated > 70%, > 90%, and ≥ 87.5% reductions in summed FLT SUV(max) and expression of phospho-Rb and Ki67, respectively, parameters necessary but not sufficient for long-term disease control. The results of the present study confirm CDK4/6 inhibition by PD0332991 at a well-tolerated dose and schedule and suggest clinical benefit in a subset of MCL patients. This study is registered at www.clinicaltrials.gov under identifier NCT00420056.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2011-10-388298

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Research works printed but not linked: 1

  1. O'Dwyer, 2011, Phase I/II pharmacodynamic trial of PD0332991 in patients with KRAS mutant colorectal cancer [abstract]., Ann Oncol, 22, PP01

Cited by

See all 303

Metadata

Authors
Leonard, J. P., LaCasce, A. S., Smith, M. R., Noy, A., Chirieac, L. R., Rodig, S. J., Yu, J. Q., Vallabhajosula, S., Schoder, H., English, P., Neuberg, D. S., Martin, P., Millenson, M. M., Ely, S. A., Courtney, R., Shaik, N., Wilner, K. D., Randolph, S., Van den Abbeele, A. D., Chen-Kiang, S. Y., Yap, J. T., & Shapiro, G. I.
Affiliations
  • Weill Cornell Medicine (US)
  • Brigham and Women's Hospital (US)
  • Fox Chase Cancer Center (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • Department of Radiology, Nuclear Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY;
  • Pfizer (United States) (US)
  • Harvard University (US)
  • Pfizer Global Research and Development, Pfizer Inc, La Jolla, CA;
  • Department of Imaging, Dana-Farber Cancer Institute, Boston, MA;
  • Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY;
Corresponding author
  • Leonard, John P.
  • LaCasce, Ann S.
Venue
Blood
Published
2012-05-17
Volume
119
Issue
20
Pages
4597-4607
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2044348066
Cited by
299
References
54
Citations by year
2026: 7 · 2025: 9 · 2024: 12 · 2023: 11 · 2022: 14 · 2021: 11 · 2020: 20 · 2019: 17 · 2018: 17 · 2017: 31 · 2016: 23 · 2015: 38 · 2014: 46 · 2013: 29 · 2012: 13
FWCI
29.30
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Pfizer
  • Dana-Farber/Harvard Cancer Center
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
Keywords
mantle cell lymphoma, CDK4/6 inhibition, palbociclib, cyclin D1, retinoblastoma protein phosphorylation, FLT-PET, FDG-PET, Ki-67, tumor cell proliferation, relapsed lymphoma, pharmacodynamic biomarkers, progression-free survival
MeSH terms
Adult, Aged, Antineoplastic Agents, Female, Humans, Male, Middle Aged, Piperazines, Prognosis, Pyridines, Substrate Specificity, Treatment Outcome, Lymphoma, Mantle-Cell, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. https://app.cochat.ai/papers/10.1182/blood-2011-10-388298
The paper
Leonard, J. P., LaCasce, A. S., Smith, M. R., Noy, A., Chirieac, L. R., Rodig, S. J., Yu, J. Q., Vallabhajosula, S., Schoder, H., English, P., Neuberg, D. S., Martin, P., Millenson, M. M., Ely, S. A., Courtney, R., Shaik, N., Wilner, K. D., Randolph, S., Van den Abbeele, A. D., . . . Shapiro, G. I. (2012). Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. https://doi.org/10.1182/blood-2011-10-388298

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.